Kura Oncology Inc (KURA)

Acute Myeloid Leukemia (AML) · registered primary completion 2031-11-01 · NCT07007312

Published 2026-09-02Market cap $1,126M7 sourced statements

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML · PHASE3 · n=1300 · recruiting

Market

fact

8 approved products already carry Acute Myeloid Leukemia (AML) on label, including Idamycin PFS, RYDAPT, Daurismo, VANFLYTA. Approval would enter an occupied market.

Source: FDA label index

Trial registry

fact

Registered design for NCT07007312: randomized, quadruple-masked, 1300 participants (estimated). Primary outcome: Nonintensive Therapy Study: (Primary Endpoint for all countries): Overall survival (OS). 3 further primary outcome(s) registered.

Source: ClinicalTrials.gov record

Runway

fact

Cash of $519M against operating outflow of $76M per quarter gives roughly 6.8 quarters of runway; the registered primary completion is 20.7 quarters out.

Source: 10-Q filed 2026-08-12

Share count and dilution

fact

88,960,619 shares outstanding against 110,627,619 if every outstanding option, warrant and convertible were exercised. In that case 19.6% of a gain in enterprise value would accrue to those holders rather than to current shareholders.

Source: antidilutive-securities disclosure, 10-Q filed 2026-08-12

Regulatory

fact

Designations disclosed: Breakthrough Therapy, Fast Track, Orphan Drug. These accelerate review and, for Orphan, confer exclusivity if approved; none is evidence of efficacy.

Source: 10-Q filed 2026-08-12

Pipeline

fact

15 distinct molecules in 6 active company-sponsored trials; Ziftomenib accounts for 5 of them at Phase 1/Phase 2/Phase 3.

Source: ClinicalTrials.gov, company as lead sponsor

Ownership and proceedings

fact

Directors and executive officers as a group hold 7.6%.

Source: DEF 14A filed 2026-04-10

Don't see a name? Request a sheet. Any US-listed biotech with a Phase 3 or a pending FDA decision — it gets built the same way, from the filings.

This sheet is dated and will not be edited. When the registered primary completion passes, its outcome is recorded on the scoreboard and a new dated sheet is published if the filings change materially.